3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
3
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
21
Lymphoma, Mantle-Cell
10
Lymphoma, Non-Hodgkin
7
Lymphoma
6
Waldenstrom Macroglobulinemia
4
Recurrence
4
Lymphoma, Follicular
4
Lymphoma, B-Cell
4
Bronchiolitis Obliterans Syndrome
3
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, B-Cell
2
Hematologic Diseases
2
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia, Lymphoid
1
Leukemia
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hepatitis B, Chronic
1
Graft vs Host Disease
1
Anemia
1
Interventions
pirtobrutinib
1
oblimersen
1
ibrutinib
1
Rituximab
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Lymphoid
×
ibrutinib
×
Clear all
NCT05254743
2026-04-20
BRUIN-CLL-314
Eli Lilly and Company
Phase 3
Recruiting
662 enrolled